BIOMED: Impella® SmartAssist Platform Launches at ESC, Designed to Further Improve Patient Outcomes
Abiomed (NASDAQ: ABMD) announces that the Impella CP® with SmartAssist technology, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available in Europe beginning at the European Society of Cardiology (ESC) Congress 2019 through a controlled roll out process at select sites.